Chromatin organization and the efficiency of nucleotide excision repair were also evaluated in the N-ras gene locus following treatment of PBMCs from quiescent SLE with vorinostat, a histone deacetylase inhibitor which has been approved by the US Food and Drug Administration for the treatment of refractory cutaneous T-cell lymphoma [24]. The gene discussed is NRAS; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.